Cagrilintide vs CJC-1295 with DAC
Extensively Studied vs Well Studied
synergistic Mechanism-based · 51% Cagrilintide helps counteract the insulin-disrupting effects of CJC-1295 with DAC. A smart combination — the insulin sensitizer mitigates metabolic side effects.
Molecular Data
Cagrilintide CJC-1295 with DAC
Weight 4,409.01 Da 3,647.28 Da
Half-life ~7 days (159-195 hours) 6-8 days
Chain 37 amino acids 30 amino acids
Type Amylin receptor agonist GHRH analog with DAC
Key Benefits
Cagrilintide
01 FDA development candidate with extensive Phase 3 data
02 Superior weight loss in combination with semaglutide (22.7%)
03 Once-weekly convenience
04 2.2% HbA1c reduction with CagriSema
CJC-1295 with DAC
01 Convenient weekly dosing
02 Sustained GH/IGF-1 elevation
03 6-8 day half-life
04 Significant body composition changes
Dosing Protocols
Cagrilintide
2.4mg weekly (after escalation) / Once weekly, same day each week
Weight Loss (Monotherapy) 2.4mg Once weekly
Weight Loss (CagriSema) 2.4mg + semaglutide 2.4mg Once weekly
Type 2 Diabetes Management 2.4mg weekly Once weekly
Dose Escalation Protocol 0.25mg → 0.5mg → 1.0mg → 1.7mg → 2.4mg Weekly increases over 16 weeks
CJC-1295 with DAC
1-2mg weekly / Once or twice weekly (e.g., Monday/Thursday for split dosing)
Conservative Anti-Aging 1mg Once weekly
Standard Protocol 2mg Once weekly
Split Dosing 1mg Twice weekly (Mon/Thu)
Loading Protocol 2mg first week, then 1mg Weekly
Side Effects
Cagrilintide
Gastrointestinal effects (nausea, vomiting, diarrhea) during initial weeks
Anti-cagrilintide antibodies develop in 46-73% but do not affect efficacy
Only 57.3% achieved maximum 2.4mg dose in REDEFINE 1 trial
CJC-1295 with DAC
Water retention
Joint pain
Carpal tunnel symptoms
Contraindications
Not recommended in pregnancy or breastfeeding
Not yet commercially available (FDA approval expected Q1 2026)
Diabetes history
Cancer history
Predisposed sleep apnea
Research Evidence
Cagrilintide CJC-1295 with DAC
Status Extensively Studied Well Studied
References 3 studies 4 studies
Latest December 2025 2025
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.